![Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fpcan.2016.57/MediaObjects/41391_2017_Article_BFpcan201657_Fig1_HTML.jpg)
Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases
![CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2011/06/capra-s-rev.png)
CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK
Indonesian Prostate Cancer Risk Calculator (IPCRC): An application for Predicting Prostate Cancer Risk (a Multicenter Study)
![Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00345-017-2150-1/MediaObjects/345_2017_2150_Fig2_HTML.gif)
Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink
![Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.](https://d3i71xaburhd42.cloudfront.net/cfb41af6cecfb5f204e79875232cee8734801010/3-Table3-1.png)
Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
![Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI](https://www.bjuinternational.com/wp-content/uploads/2016/11/AOTWNov-2-FI.jpg)
Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI
![Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2009/12/mskcc-image-d.jpg?w=584)
Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK
![A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0302283812008342-gr2.jpg)
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect
![A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc](https://www.urotoday.com/images/stories/Beyond_the_Abstract/bta_zhu_fig1c.jpg)